Diseases & Indications

Peanut allergy is one of the most common and dangerous food allergies in children, with the risk of anaphylaxis on accidental exposure. Desensitization approaches aim to raise the threshold dose a child can tolerate. Epicutaneous (skin-patch) immunotherapy is being developed specifically to reduce reaction severity in young children.

Obesity is a chronic metabolic disease and the highest-value therapeutic market in pharma, reshaped by incretin (GLP-1) medicines that deliver double-digit weight loss. Competition now centers on oral small molecules, tolerability, and durability of weight loss after stopping or switching therapy. Percent body-weight change is the headline endpoint.

Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by itch, barrier dysfunction, and type-2 immune activation. Efficacy is judged by skin-clearance measures such as EASI-75 and IGA. The space is crowded with biologics and oral agents, so new entrants must clear a high efficacy and safety bar.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, causing patchy to complete hair loss with major psychosocial impact. The Severity of Alopecia Tool (SALT) score is the standard regrowth endpoint. Restoring immune balance — including regulatory T-cell function — is an emerging approach alongside JAK inhibition.

Central precocious puberty (CPP) is the early onset of puberty driven by premature activation of the hypothalamic–pituitary–gonadal axis. Standard care suppresses gonadotropins with GnRH agonists to halt premature development and preserve adult height. Longer-interval depot formulations aim to reduce the injection burden on children and families.

Anti-glomerular basement membrane (anti-GBM) disease, also called Goodpasture disease, is a rare, rapidly progressive autoimmune disorder in which IgG autoantibodies attack the kidneys and lungs. Untreated, it causes fulminant kidney failure within days to weeks. Rapidly removing pathogenic IgG is the rationale for enzyme-based antibody cleavage on top of standard immunosuppression.

Duchenne muscular dystrophy (DMD) is a severe, X-linked neuromuscular disease caused by mutations in the DMD gene that abolish functional dystrophin protein. Boys progressively lose muscle function, with respiratory and cardiac failure being the leading causes of death. Modern programs pursue exon-skipping to restore partial dystrophin and cell therapies to slow skeletal and cardiac decline.

Desmoid tumors (aggressive fibromatosis) are rare, locally aggressive soft-tissue tumors that infiltrate surrounding structures but do not metastasize. Many are driven by aberrant Wnt/β-catenin signaling, and gamma-secretase inhibition of the Notch pathway has emerged as a targeted strategy. Progression-free survival and tumor-volume response are the key efficacy readouts.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and a major cause of cancer death worldwide. After progression on immunotherapy and chemotherapy, options are limited and overall survival is the decisive endpoint. Combining DNA-damage-response inhibitors with checkpoint blockade is an experimental strategy to re-sensitize tumors.

Stargardt disease type 1 (STGD1) is the most common inherited macular dystrophy, caused by mutations in the ABCA4 gene. Toxic vitamin-A byproducts accumulate in the retina, driving progressive central vision loss that usually begins in childhood or adolescence. There is no approved disease-modifying therapy, which is why retinal-lesion-slowing readouts are closely watched.

Thyroid eye disease (TED) is an autoimmune orbital disorder, usually associated with Graves' disease, that causes proptosis (eye bulging), inflammation, and diplopia. Proptosis responder rate is the standard efficacy endpoint. Approaches that lower pathogenic IgG autoantibodies have been explored as steroid-sparing options.

Chronic rhinosinusitis without nasal polyps (CRSsNP) is a persistent inflammation of the sinuses causing nasal obstruction, facial pressure, and reduced quality of life, with fewer approved targeted therapies than the polyp-positive form. Neutrophil-driven inflammation is implicated in much of the disease. Symptom scores and sino-nasal outcome measures are the principal endpoints.

Alpha-1 antitrypsin deficiency (AATD) is an inherited disorder, caused by SERPINA1 gene variants, in which low levels of the protease inhibitor alpha-1 antitrypsin leave the lungs vulnerable to enzymatic damage and early-onset emphysema. Augmentation therapy aims to restore protective protein levels in the lung. Lung-function preservation is the long-term goal of treatment.

Dermatomyositis is an autoimmune inflammatory myopathy marked by characteristic skin rash and progressive muscle weakness, frequently involving an interferon-driven immune signature. Outcomes are commonly measured with the Total Improvement Score (TIS). Therapies that dampen the JAK/TYK2–interferon axis are an active area of development.

Systemic lupus erythematosus (SLE) is a chronic, multi-organ autoimmune disease with a relapsing–remitting course and substantial unmet need. Trials typically read out on composite responder indices such as SRI-4. SLE has historically been one of the hardest indications in drug development, with a long track record of late-stage failures.